Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Rhea-AI Summary

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced the engagement of ProConsul Capital to provide investment marketing consulting services, effective February 6th, 2025. The agreement includes a monthly fee of $6,000 and stock options to be granted to ProConsul, with details to be announced later. The contract operates on a month-to-month renewal basis and can be terminated by either party with 30 days written notice.

Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options will be determined at a later date, and announced by the Company. The agreement is renewable on a month-to-month basis unless terminated by either party on 30 days written notice.

About Hemostemix

Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal, and cardiomyocyte cell precursors, to treat no-option patients worldwide.

Learn more: www.hemostemix.com

Contact: Thomas Smeenk, President & CEO - tsmeenk@hemostemix.com | (905) 580-4170
Stock Information: (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0)

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240246

FAQ

What is the monthly fee Hemostemix (HMTXF) will pay ProConsul Capital for marketing services?

Hemostemix will pay ProConsul Capital a monthly fee of $6,000 for investment marketing consulting services.

When does ProConsul Capital's marketing agreement with Hemostemix (HMTXF) begin?

The marketing agreement between ProConsul Capital and Hemostemix begins on February 6th, 2025.

What are the termination terms for Hemostemix's (HMTXF) agreement with ProConsul Capital?

The agreement can be terminated by either party with 30 days written notice and operates on a month-to-month renewal basis.

Will ProConsul Capital receive stock options from Hemostemix (HMTXF)?

Yes, Hemostemix has agreed to grant stock options to ProConsul Capital, with the number and terms to be determined and announced at a later date.